Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/8202
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMarikar, Faiz-
dc.contributor.authorZi-Chun, Hua-
dc.date.accessioned2024-11-20T02:44:25Z-
dc.date.available2024-11-20T02:44:25Z-
dc.date.issued2023-
dc.identifier.issn2618-642X-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/8202-
dc.description.abstractMore than a century ago, the very first adverse human health effects of Fas-associated death domain (FADD) were reported with cell death. It is most well-known role in apoptosis, FADD has also been seen to play a role in other processes including proliferation, cell cycle regulation, and development. It contains two main domains: A C terminal death domain (DD) and an N terminal death effector domain. On stimulation by the Fas ligand, the Fas receptor trimerises. Many receptors, including Fas, contain a cytoplasmic DD and are therefore named death receptors. FADD binds to the DD of this trimeric structure through its DD leads to apoptosis. FADD also plays a role in regulating necroptosis, a process requiring the serine/threonine kinases. Activated caspase 8 cleaves these kinases, inhibiting necroptosis. Application of Taxol is a drug used in anticancer therapies due to its ability to interfere with microtubule assembly, which leads to cell cycle arrest. It has been suggested that inhibition of FADD might work as a potential targeted therapy for drug-resistant ovarian cancer.en_US
dc.language.isoen_USen_US
dc.publisherInternational Journal of Medical Biochemistryen_US
dc.relation.ispartofseriesReview;124-132-
dc.subjectApoptosisen_US
dc.subjectdrug effecten_US
dc.subjectfas-associated death domainen_US
dc.subjectgeneticsen_US
dc.titleAdapter protein – FADD bridges the apoptosisen_US
dc.typeArticleen_US
Appears in Collections:Vol 6 No 2 (2023)

Files in This Item:
File Description SizeFormat 
124 - 132.pdf2.98 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.